2024年世界肺癌大会(WCLC)将于美国当地时间2024年9月7日至10日在SAN DIEGO盛大召开。由国际肺癌研究协会(IASLC)、中国临床肿瘤学会(CSCO)及中国肺癌防治联盟(CAALC)联合举办的IASLC-CSCO-CAALC联席会议已成为全球学者洞悉中国肺癌领域最新...
【中国强音】2024 WCLC口头报告环节中国研究摘要要点速览! 2024年世界肺癌大会(WCLC)将于美国当地时间2024年9月7日至10日在SAN DIEGO盛大召开。此次大会将汇聚来自世界各地的顶尖专家学者,共同探讨肺癌研究的最新进展和诊疗技术的创新。多项中国研究成...
[2]Cascone T, et al. Neocoast-2: efficacy and safety of neoadjuvant durvalumab (d) + novel anticancer agents + CT and adjuvant d ± novel agents in resectable NSCLC. Presented at: 2024 IASLC World Conference on Lung Cancer; September 7-10, 2024; San Diego, California. Abstract PL02.07 ...
地点/Venue: San Diego Convention Center San Diego, CA USA 组织/Organized by: International Association for the Study of Lung Cancer (IASLC) The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 dele...
San Diego, CA USA 组织/Organized by: International Association for the Study of Lung Cancer (IASLC) The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries...
The 2024 World Conference on Lung Cancer (WCLC), meeting in San Diego, California, from September 7 to 10, 2024, will feature practice-changing data and discussion in the lung cancer space. Recent years have seen encouraging strides in the management of l...
Dr Patel:I’m Sandip Patel MD, Professor of Medical Oncology at the University of California San Diego. I am one of the co-Chairs of WCLC 2024 here in San Diego. It is a pleasure to be joining you to discuss the data. IASLC is an international organization. Cancer is the biggest prob...
[1].Ruiter G. et al. Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2-Mutant NSCLC. presented at WCLC, San Diego, 7-10 September, 2024. 声明: 1. 本新闻稿旨在促进医药信息的沟通和交流,仅供医疗卫生专业人士参阅,非广告用途。
参考文献Zhou C, Chen J, Wu L, et al. Phase 3 study of ivonescimab (AK112) vs. pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC: primary analysis of HARMONi-2. Presented at: 2024 World Conference on Lung Cancer; September 8, 2024; San Diego, CA. Accessed Septem...
1.Forde P,Peters S,Donington J,et al.Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC:Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816.Presented at:2024 IASLC World Conference on Lung Cancer;September 7-10,2024;San Diego,CA.Abstract PL02.08. ...